PerioPatch

All those people who have suffered from periodontal diseases or gingivitis at some point in their lives would never like to face such diseases again, considering the fact that one has to go through a lot of pain and difficulties.

In the simplest way possible, periodontal diseases can be described as the infections and inflammations that occur near teeth and gumline, which have the capacity or potential to destroy the tooth when they reach an extreme situation.

However, if we look at them more technically, periodontal diseases range from mild inflammations to gingivitis to periodontists which are caused due to bacteria and can have a negative effect on periodontal tissues like gingiva, cementum, and periodontal ligament etc.

Periodontal diseases stem from plaque, which is caused or formed by bacteria that live in the mouth. Plaque can generally be described as a sticky and colorless stuff found on the teeth, that is produced by bacteria.

Though it’s true that plaque can be removed easily through timely brushing and regular flossing, however if it still stays in your teeth, it starts hardening and converts into tarter after a period of time. Remember one thing, tarter cannot be removed by you and in order to get rid of it, you have to go to a dentist for a dental cleaning.

Significance of PerioPatch in Healing Periodontal Diseases

Though there are a lot of ways to overcome, prevent or treat these oral diseases, but they are surely going to take sufficient time. However, if you think that it’s just impossible to find a quick treatment for periodontal diseases you are absolutely wrong as you can always use ‘PerioPatch’ a product designed by Izun Pharmaceuticals for treating oral problems like gingivitis and periodontists etc.

PerioPatch is an incredibly useful topical patch which helps in providing tremendous relief from oral inflammation caused by periodontal diseases such as gingivitis and periodontists. Once this topical patch is correctly applied over the affected area, it starts working magically and reacts towards healing the inflammation very quickly.

As soon as PerioPatch is made to sit on the inflamed parts on the gumline, its distinctive properties start protecting the tissue by extracting the inflammatory exudates that stay in the tissue as well as in Gingival Crevicular Fluid – which is often addressed with its acronym GCF. It’s extremely important that inflammatory exudates are effectively absorbed, otherwise, they help in sustaining the inflammation.

Hence, in order to get rid of inflammatory cytokines (which help in stimulating and starting the periodontal disease cycle) from crevicular space, it’s important to use PerioPatch.

If you want to understand how fast PerioPatch works, let me tell you that within an hour one patch can absorb approximately 140µl of Gingival Crevicular Fluid.

According to the variety of research studies conducted at renowned institutions like the University of Michigan, and Columbia University PerioPatch helps a great deal when it comes to reducing and healing the inflammation caused because of oral diseases. However, the best part of using PerioPatch is that it has no side effects.

PerioPatch®, a novel oral trans-mucosal patch system that reduces inflammation and promotes tissue repair, has been shown to significantly reduce pocket depth (PD) and to generate an increase in attachment level (AL) in patients with advanced periodontal disease

Izun Pharmaceuticals Corporation an emerging specialty pharmaceutical company in New York which focuses on developing best in class pharmaceutical products derived from botanical sources today reported the results of a clinical study conducted at the University of North Carolina Chapel Hill (“UNC”). The 80 patient study compared scaling and root planing (SRP) in conjunction with PerioPatch treatment versus SRP alone. The study demonstrated that PerioPatch treatment significantly reduced pocket depth (PD) and increased attachment level (AL) gain relative to control group in treated patients with advanced periodontal disease.

David W. Paquette, DMD, MPH, DMSc, of Stony Brook University School of Dental Medicine, who designed and oversaw the clinical trial remarked, “This clinical study demonstrates that adjunctive PerioPatch treatment reduces the signs of inflammatory periodontal disease beyond conventional therapy. This outcome is a major improvement in the management of periodontal disease in patients. Additionally, PerioPatch represents the first topical anti-inflammatory product that may be applied by both professionals and patients.”

These findings clinically confirm animal data and other clinical trials that the use of PerioPatch will assist in repairing the damage to the gums that develops from periodontal disease. Both primary (reduction of PD) and secondary (AL gain) endpoints of the study were met and were statistically significant. These significant improvements were evident at one month and continued to improve at two and three months, which represented the completion of the evaluation period. The current data extend previously published clinical reports which demonstrated that the PerioPatch can improve the above parameters as well as decrease bleeding upon probing and gingival inflammation at 2, 4 and 6 weeks.

Pre-clinical studies in animal trials demonstrated that treatment with PerioPatch results in more rapid healing as a result of increased collagen production and accelerated tissue revascularization. Such data correlate well with the gingival repair that was noted both in the UNC study and in previously conducted clinical trials.

Dr. William Levine, CEO and Chairman of Izun Pharmaceuticals Corp. stated, “Results of the UNC study support the conclusion that PerioPatch is a breakthrough treatment for periodontal disease and is the most effective topical oral product for reducing gingival inflammation and promoting healing. PerioPatch should thus be integrated into the routine treatment protocol for periodontal disease, a market with estimated annual sales of $2 billion in 2017.”

PerioPatch has regulatory approval in the United States and Canada, as well as in the European Union.